TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Amneal Pharmaceuticals ( (AMRX) ) just unveiled an announcement.
Amneal Pharmaceuticals reported strong financial results for the second quarter of 2025, with a net revenue of $725 million, marking a 3% increase from the previous year. The company also announced a successful debt refinancing, which reduces interest costs and extends maturities, positioning Amneal for long-term growth. The quarter was highlighted by the commercial success of CREXONT® for Parkinson’s disease and the FDA approval of Brekiya® autoinjector for migraines, contributing to a 23% increase in specialty net revenue. Amneal raised its full-year 2025 financial guidance, reflecting confidence in its diversified pharmaceutical business and growth strategies.
The most recent analyst rating on (AMRX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.
Spark’s Take on AMRX Stock
According to Spark, TipRanks’ AI Analyst, AMRX is a Neutral.
Amneal Pharmaceuticals’ score is driven by a combination of strategic financial restructuring and positive corporate developments, which are countered by high leverage and profitability challenges. While technical performance shows potential stabilization, valuation metrics highlight ongoing market value concerns.
To see Spark’s full report on AMRX stock, click here.
More about Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of over 280 pharmaceutical products, primarily in the United States. The company operates in the Affordable Medicines segment, focusing on complex product categories and therapeutic areas such as injectables and biosimilars, and in the Specialty segment, which is centered on branded pharmaceuticals for central nervous system and endocrine disorders. Additionally, through its AvKARE segment, Amneal distributes pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets.
Average Trading Volume: 1,627,635
Technical Sentiment Signal: Hold
Current Market Cap: $2.45B
Find detailed analytics on AMRX stock on TipRanks’ Stock Analysis page.